Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
5-fluorouracil + leucovorin + oxaliplatin + bevacizumab
- Development stage
- Unknown
- Lead developer
- Southwestern Regional Medical Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy and targeted therapy regimen consisting of chronomodulated FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) plus bevacizumab (Avastin). Evaluated by Southwestern Regional Medical Center, the regimen utilizes a chronomodulated delivery system, which schedules drug administration to coincide with the patient's circadian rhythms to potentially minimize toxicity and enhance therapeutic efficacy. 5-fluorouracil is a pyrimidine analog that inhibits thymidylate synthase; leucovorin is a folinic acid derivative that stabilizes the binding of 5-FU to its target; oxaliplatin is a platinum-based agent that forms DNA cross-links; and bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis. This specific combination was investigated in Phase 2 clinical trials for the treatment of metastatic or unresectable colorectal cancer.
- Brand names
- Avastin
- Other names
- ChronoFOLFOX + bevacizumabChronoFOLFOX + AvastinFOLFOX-bevacizumabFOLFOX-Avastin5-FU + LV + oxaliplatin + bevacizumab
02
Targets
Beyond the preview
Go deeper on 5-fluorouracil + leucovorin + oxaliplatin + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 5-fluorouracil + leucovorin + oxaliplatin + bevacizumab.